tbuckley/cabot-search huggingface dataset:
Circling Back for the Diagnosis
Authors: Joseph Rencic, Mengyu Zhou, Gerald Hsu, Gurpreet Dhaliwal
Journal: New England Journal of Medicine (2017)

A 28-year-old man presented to the emergency department with abdominal pain, nausea, and vomiting. He reported 6 weeks of intermittent upper and lower abdominal pain on the right side, which worsened with food intake and usually improved within 1 to 2 hours with antacids.
Stent-over-sponge (SOS): a novel technique complementing endosponge therapy for foregut leaks and perforations
Authors: Piero Valli, Joachim Mertens, Arne Kröger, Christoph Gubler, Christian Gutschow, Paul Schneider, Peter Bauerfeind
Journal: Endoscopy (2017)

Abstract Background and study aims Endoluminal vacuum therapy (EVT) has evolved as a promising option for endoscopic treatment of foregut wall injuries in addition to the classic closure techniques using clips or stents. To improve vacuum force and maintain esophageal passage, we combined endosponge treatment with a partially covered self-expandable metal stent (stent-over-sponge; SOS). Patients and methods Twelve patients with infected upper gastrointestinal wall defects were treated with the SOS technique. Results Indications for SOS were anastomotic leakage after surgery (n = 11) and chronic foregut fistula (n = 1). SOS treatment was used as a first-line treatment in seven patients with a success rate of 71.4 % (5/7) and as a second-line treatment after failed previous EVT treatment in five patients (success rate 80 %; 4/5). Overall, SOS treatment was successful in 75 % of patients (9/12). No severe adverse events occurred. Conclusion SOS is an effective method to treat severely infected foregut wall defects in patients where EVT has failed, and also as a first-line treatment. Comparative prospective studies are needed to confirm our preliminary results.
TCT-347 Neurologic Events in Patients Treated with Surgical Versus Transfemoral Transcatheter Aortic Valve Replacement: Insights from the PARTNER (Placement of Aortic Transcatheter Valves) Trial
Authors: Samir Kapadia, Chetan Huded, Susheel Kodali, Lars Svensson, E. Murat Tuzcu, D.Craig Miller, Vinod Thourani, Howard Herrmann, Michael Mack, Molly Szerlip, Raj Makkar, John Webb, Craig Smith, Jeevanantham Rajeswaran, Eugene H. Blackstone, Martin Leon
Journal: Journal of the American College of Cardiology (2017)
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination Survey
Authors: O Landgren, B I Graubard, S Kumar, R A Kyle, J A Katzmann, K Murata, R Costello, A Dispenzieri, N Caporaso, S Mailankody, N Korde, M Hultcrantz, T M Therneau, D R Larson, J R Cerhan, S V Rajkumar
Journal: Blood Cancer Journal (2017)

Abstract We studied the prevalence of monoclonal gammopathy of undetermined significance (MGUS) in younger individuals, age 10–49 years, using samples from the National Health and Nutritional Examination Survey (NHANES) III. NHANES prevalence rates were standardized to the 2000 US total population. Among 12 372 individuals (4073 blacks, 4146 Mexican-Americans, 3595 whites, and 558 others), MGUS was identified in 63 persons (0.34%, 95% CI 0.23–0.50). The prevalence of MGUS was significantly higher in blacks (0.88%, 95% CI 0.62–1.26) compared with whites (0.22%, 95% CI 0.11–0.45), P =0.001. The prevalence of MGUS in Mexican-Americans was at an intermediate level (0.41%, 95% CI 0.23–0.73). The disparity in prevalence of MGUS between blacks and whites was most striking in the 40–49 age-group; 3.26% (95% CI 2.04–5.18) versus 0.53% (95% CI 0.20–1.37), P =0.0013. There was a trend to earlier age of onset of MGUS in blacks compared with whites. MGUS was seen in only two persons in the 10–19 age-group (both Mexican-American), and in three persons in the 20–29-year age-group (all of whom were black). In persons less than 50 years of age, MGUS is significantly more prevalent, with up to 10 years earlier age of onset, in blacks compared with whites.
Limits on prescribing will harm rural and poorer patients, doctors warn
Authors: Gareth Iacobucci
Journal: BMJ (2017)

Proposals to limit GPs’ prescribing of over-the-counter (OTC) drugs will disproportionately harm patients on lower incomes and those in rural areas, the Dispensing Doctors’ Association (DDA) has warned.1

The association, which represents 1290 dispensing practices around the UK, added that the proposals could create substantial extra work for overstretched general practices, which will have to oversee drug changes and respond to patients’ concerns.

The warnings came in a response to NHS England’s consultation23 on plans to restrict GPs’ prescribing of 3200 products that are available without prescription, such as paracetamol, antifungal treatments, and eczema creams. The NHS currently …
Dual-Task Gait and Incident Dementia
Authors: Sirwan K. L. Darweesh, Vincentius J. A. Verlinden, M. Arfan Ikram
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Review: In adult inpatients with mild or moderate acute pancreatitis, early feeding may reduce length of stay
Authors: Dennis Yang, Christopher E. Forsmark
Journal: Annals of Internal Medicine (2017)

ACP Journal Club17 October 2017Review: In adult inpatients with mild or moderate acute pancreatitis, early feeding may reduce length of stayDennis Yang, MD, Christopher E. Forsmark, MDDennis Yang, MDUniversity of Florida, Gainesville, Florida, USA (D.Y., C.E.F.)Search for more papers by this author, Christopher E. Forsmark, MDUniversity of Florida, Gainesville, Florida, USA (D.Y., C.E.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2017-167-8-044 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationVaughn VM, Shuster D, Rogers MAM, et al. Early versus delayed feeding in patients with acute pancreatitis: a systematic review. Ann Intern Med. 2017;166:883-92. https://pubmed.ncbi.nlm.nih.gov/28505667Clinical Impact RatingsHospitalists: Gastroenterology: References1 Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108:1400-15; 1416. [PMID: 23896955] Google Scholar2 Bakker OJ, van Brunschot S, van Santvoort HC, et al.; Dutch Pancreatitis Study Group. Early versus on-demand nasoenteric tube feeding in acute pancreatitis. N Engl J Med. 2014;371:1983-93. [PMID: 25409371]. Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Florida, Gainesville, Florida, USA (D.Y., C.E.F.)This article was published at Annals.org on 3 October 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 October 2017Volume 167, Issue 8Page: JC44KeywordsAcute pancreatitisAdverse eventsDietLength of stayMortalityNutritionPancreatitisSystematic reviewsVomiting ePublished: 17 October 2017 Issue Published: 17 October 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
TCT-65 Reclassification of revascularization strategy with instantaneous wave-free ratio and fractional flow reserve: A report from the iFR-SWEDEHEART study
Authors: Pontus Andell, Ole Frobert, Evald Christiansen, Ingibjorg Gudmundsdottir, Lennart Sandhall, David Erlinge, Matthias Götberg
Journal: Journal of the American College of Cardiology (2017)
Randomized phase II study of abiraterone acetate (AA) maintenance in combination with docetaxel after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): Preliminary safety results of first line AA treatment—ABIDO-SOGUG Trial.
Authors: Ignacio Duran, Enrique Grande, Daniel E. Castellano, Albert Font, M Isabel Sáez, Javier Puente, Carmen Santander, María José Méndez-Vidal, Jose Angel Arranz Arija, Begona Mellado, Alfredo Sanchez-Hernandez, Emilio Esteban, Aranzazu Gonzalez del Alba, Martin Lázaro Quintela, Alfonso Gomez de Liaño, Javier Cassinello, Miguel Angel Climent
Journal: Journal of Clinical Oncology (2015)

e16022 Background: Docetaxel (D) is the standard treatment for symptomatic or aggressive mCRPC. Abiraterone acetate (AA) in combination with prednisone improves OS and rPFS in mCRPC chemotherapy (CT) naïve patients (pts) with asymptomatic or minimally symptomatic disease (Ryan CJ, 2013; ZYTIGA Janssen Biotech, Inc., 2012). This study aims to evaluate efficacy and safety of AA maintenance in combination with D after disease progression to first line AA in mCRPC. Methods: This is a randomized, phase II, open-label study conducted in CT naïve mCRPC pts progressing after AA treatment. Pts with confirmed histologically or cytologically adenocarcinoma of the prostate, metastatic disease other than visceral, progression to previous castration, ECOG PS 0-1, testosterone < 50 ng/dL and adequate, hematologic, hepatic, and renal function were included to receive AA treatment (1000 mg qd plus prednisone 10 mg qd) until disease progression determined by PSCWG2 criteria. In a second stage pts will be randomized to receive D 75 mg/m2 plus prednisone 10 mg/d combined with AA 1000 mg/d (arm A) or D 75 mg/m2plus prednisone 10 mg/d (arm B), in 21 day cycles. Results: Up to date, 118 pts have been enrolled. Median age was 71 years, 57.7% had ECOG 0 and 70.3% had bone metastases. Median baseline PSA and testosterone levels were 55.7 ng/mL and 8.7 ng/dL; 56.9% of pts had pain (median VAS 1.0). Median time from diagnosis of metastatic disease was 15.6 months. 111 pts received 563 cycles of AA, median 5, range 1-11. Median dose intensity was 100%. One pt discontinued treatment due to toxicity (Grade 3 liver toxicity). Grade 3 toxicities were: hypertension (1.8%), ALT increased (1.8%), hypophosphatemia (0.9%), cardiac insufficiency (0.9%) and glucose increased (0.9%). Main toxicities all grades were: asthenia (8.1%), ALT increased (5.4%), anemia (5.4%), alkaline phosphatase increased (4.5%) and hypertension (4.5%). No grade 4 toxicities were reported. Conclusions: AA is a safe treatment as first line in pts with mCRPC. Toxicities, most of them mild, are manageable. Clinical trial information: NCT02036060.
Long-term effect of critical illness after severe paediatric burn injury on cardiac function in adolescent survivors: an observational study
Authors: Gabriel Hundeshagen, David N Herndon, Robert P Clayton, Paul Wurzer, Alexis McQuitty, Kristofer Jennings, Ludwik K Branski, Vanessa N Collins, Nicole Ribeiro Marques, Celeste C Finnerty, Oscar E Suman, Michael P Kinsky
Journal: The Lancet Child & Adolescent Health (2017)
TCT-258 Impact of Complications During Chronic Total Occlusion Angioplasty on Hospitalization Costs and Length of Stay: Insights from the OPEN-CTO Registry
Authors: Adam Salisbury, J. Aaron Grantham, Qingrui Meng, Suzanne Arnold, Hemal Gada, Suzanne Baron, William Lombardi, Dimitri Karmpaliotis, Jeffrey Moses, John Spertus, David Cohen
Journal: Journal of the American College of Cardiology (2017)
StrongLifts 5×5 Workout: mobile app user guide
Authors: Nash Anderson, Saara Stevenson, Jenni Brozena
Journal: British Journal of Sports Medicine (2017)

iOS version: 2.87. Requires iOS 9.0 or later. Compatible with iPhone, iPad and iPod touch.

Android current version 2.4.9. Requires Android 4.0 and up.

Free. In-app products $1.99–$9.99 per item.

As discussed in Robert Sallis’s ‘Exercise is Medicine’ paper, ‘There should be a merging of the fitness industry with the healthcare industry, so that patients can be better helped to find an appropriate fitness regimen’.1 StrongLifts 5×5 is a mobile app that can be used to promote the resistance training aspect of physical activity. Resistance training is an essential aspect to improving public health.2 With >10 000 5-star reviews on the iTunes App store and 500 000 to 1 million downloads for Android, StrongLifts 5×5 is a popular gym training mobile application. This app can be used for recommending moderate physical activity to patients. An understanding of how this app works is essential for clinicians.

Based on the principles of exercise selection and prescription, the 5×5 app recommends various compound movements. Movements vary between the deadlift, squat, bench press, overhead press and bent-over row (figure 1).



Figure 1 
Choice of various compound exercises.



The 5×5 app also provides instructional videos on how to perform the above compound exercises (figure 2).

This approach is not personalised to a great degree. This …
Conceptualizing Partnerships Between Private Payers and Medicare for Quality Improvement Initiatives
Authors: Darrell A. Campbell, Greta L. Krapohl, Michael J. Englesbe
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
OP0055 Sulfasalazine improves the number of flares of acute anterior uveitis over a one year period
Authors: S Muñoz-Fernández, V Hidalgo, G Bonilla, J Fernández, A Schlincker, AB Larqué, A Fonseca, E Martín-Mola
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Sulfasalazine is used in RA, but its role in uveitis is not well established. <h3>Objectives</h3> To study the efficiency of sulfasalazine (SSZ) in the treatment of recurrent flares of acute anterior uveitis (AAU) over a one year period. <h3>Methods</h3> From June of 1997 to October 2000, 376 patients with uveitis have been attended by Ophthalmologists and Rheumatologists in our outpatient Uveitis Unit according to a protocol based on the pattern of uveitis and clinical symptoms of the patient. Data were prospectively recorded. The criteria to start treatment were: 1) The presence of three or more flares of AAU in the previous year or 2) Recurrence of the uveitis in less than three months from the previous episode. Exclusion criteria to start SSZ were uveitis due to infectious or malignant causes or the presence of any contraindications to this drug. SSZ was started at 500 mg per day and gradually increased untill a dose of 2 g per day. If inadecuate response, the dose was increased untill 3 g. The major outcome was defined as the number of flares of uveitis over a one year period compared in the same group of patients with the flares of the previous year without SSZ, followed prospectively in our unit. Wilcoxon test was used for the statistical study. <h3>Results</h3> Eleven patients were in SSZ treatment (5 men, 6 women; 6 ankylosing spondylitis 2 idiopatic uveitis, one Reiter´s syndrome, one intestinal inflammatory disease and one juvenil chronic arthritis). Three of them started SSZ for other reasons than uveitis or in other services of the hospital and were then excluded of the analysis. In the remaining 8 patients, the mean number of AAU flares in the pre-SSZ year was 3.5 (ranging from 3 to 4 flares, SD 0.5). After a one year of treatment, the mean of flares was reduced to 0.6 (ranging from 0 to 2 flares, SD 0.9) that was found to be significant (p = 0.011). Only one patient was found to be a non-responder. Other two patients were considered partially responderes with a reduction from 4 to 2 and from 3 to 1 flares respectively in comparison of the pre and post-treatment one year period. The other 6 patients did not have any new flare of uveitis during the one year SSZ treatment. We found only two adverse events, both with increased transaminase profiles that did not result in discontinuation of the therapy. <h3>Conclusion</h3> SSZ treatment reduce the number of flares over a one year period in patients with recurrent AAU.
Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells
Authors: Xiaoqi Huo, Shuanglin Han, Guang Wu, Olivier Latchoumanin, Gang Zhou, Lionel Hebbard, Jacob George, Liang Qiao
Journal: Molecular Cancer (2017)

Hepatocellular carcinoma (HCC) is one of the most common malignant tumours with a poor prognosis worldwide. While early stage tumours can be treated with curative approaches such as liver transplantation or surgical resection, these are only suitable for a minority of patients. Those with advanced stage disease are only suitable for supportive approaches and most are resistant to the conventional chemotherapy or radiotherapy. Liver cancer stem cells (LCSCs) are a small subset of cancer cells with unlimited differentiation ability and tumour forming potential. In order to develop novel therapeutic approaches for HCC, we need to understand how the cancer develops and why treatment resistance occurs. Using high-throughput sequencing techniques, a large number of dysregulated long noncoding RNAs (lncRNAs) have been identified, and some of which are closely linked to key aspects of liver cancer pathology, progression, outcomes and for the maintenance of cancer stem cell-like properties. In addition, some lncRNAs are potential biomarkers for HCC diagnosis and may serve as the therapeutic targets. This review summarizes data recently reported lncRNAs that might be critical for the maintenance of the biological properties of LCSCs.
Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma
Authors: J Bae, T Hideshima, G L Zhang, J Zhou, D B Keskin, N C Munshi, K C Anderson
Journal: Leukemia (2017)
TCT-407 Treatment of acute coronary syndrome patients with a sirolimus-eluting bioresorbable polymer-coated stent: 1-year clinical outcomes from the e-Ultimaster registry (on behalf of the e-Ultimaster investigators)
Authors: Orazbek Sakhov, Murat Kuzhukeyev, Almat Kodasbayev, Aizhan Kulanbayeva, Saule Dairbekova
Journal: Journal of the American College of Cardiology (2017)
Aryl hydrocarbon receptor interacting protein (AIP) is a novel tumor susceptibility gene involved in pituitary tumorigenesis in pediatric and adult patients
Authors: Marianthi Georgitsi, Ernesto De Menis, Salvatore Cannavo, Auli Karhu, Lauri Aaltonen
Journal: Cancer Research (2008)

1209   Pituitary adenomas are common benign neoplasms of the anterior pituitary gland. Prolactin (PRL) and growth hormone (GH)-secreting adenomas are the most frequent oversecreting tumors. GH oversecretion leads to acromegaly/gigantism; PRL oversecretion can cause delayed sexual development and infertility. These adenomas are mainly sporadic, but ~3% occur as components of familial endocrine cancer syndromes, such as Multiple Endocrine neoplasia Type 1 (MEN1) and Carney complex. Combining chip-based technologies and genealogy data, we identified germline mutations in the  aryl hydrocarbon receptor interacting protein  ( AIP ) gene as the underlying cause for a novel form of autosomal dominant pituitary adenoma disease in Northern Finland, with incomplete penetrance (namely pituitary adenoma predisposition-PAP). PAP patients are typically diagnosed with acromegaly/gigantism at young age ( AIP  mutations has not been investigated in a tailored pediatric series encompassing different types of pituitary adenomas. For this purpose, we studied a unique population-based cohort of 38 pediatric patients systematically collected in two medical centres in Italy. Inclusion criteria for the cases were either age at diagnosis less than 18 years, or clinical evidence of adenoma development before the age of 18 years. Mean age at diagnosis was 17.95 years (median 18 ± 2.82, range 12-24). Macroadenomas accounted for nearly three times the number of microadenomas. Secreting tumors predominated, representing 82% of all adenomas in the cohort. Genomic DNA was analyzed by PCR amplification and direct sequencing, as well as by MLPA. Germline  AIP  mutations account for 7.9% of all adenomas, and for 33.3% of GH-secreting tumors, in the present series. While no changes were found among non-GH-secreting adenomas,  germline  AIP  mutations appear to be common in children and adolescents with GH-secreting tumors. Further work on the functional role of  AIP  should prove informative in revealing key cellular processes involved in pituitary tumorigenesis.
<i>HLA-Cw6</i> and psoriasis
Authors: L. Chen, T.-F. Tsai
Journal: British Journal of Dermatology (2017)

Summary Psoriasis is a multifactorial disease with a strong genetic background. HLA-Cw6 is one of the most strongly associated psoriasis susceptibility alleles. It is repeatedly observed to affect disease course, phenotypic features, severity, comorbidities and treatment outcomes. To the best of our knowledge, the roles of HLA-Cw6 in psoriasis have not yet been thoroughly reviewed. The worldwide frequency of the HLA-Cw6 allele varies greatly, with it being generally higher in white people than in Asians. The allele is associated with type I early-onset psoriasis. Stress, obesity and streptococcal pharyngitis are commonly observed in HLA-Cw6-positive patients. Phenotypically, HLA-Cw6 has been found to be associated with guttate psoriasis. In addition, patients carrying the allele are more likely to have arm, leg and trunk involvement, and the Koebner phenomenon. Patients with psoriatic arthritis with HLA-Cw6 more often have early onset and tend to show cutaneous symptoms before musculoskeletal symptoms. HLA-Cw6-positive patients have been shown in several studies to be more responsive to methotrexate and ustekinumab. However, this difference in ustekinumab efficacy was only moderate in a post-hoc analysis of a pivotal phase III study. HLA-Cw6 positivity also tends to be less frequent in high-need patients who fail conventional therapy. Small studies have also investigated the role of HLA-Cw6 in remission of psoriasis during pregnancy, and with the comorbidities of photosensitivity and atherosclerosis. Given the diverse nature of psoriasis pathogenesis, as well as the difference of HLA-Cw6 positivity in different ethnic groups, more studies are needed to confirm the role of HLA-Cw6 in psoriasis.